0NLV Stock Chart & Stats
€6.20
€0.00(0.00%)
At close: 4:00 PM EST
€6.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.66 - €9.80
Previous CloseN/A
Volume0.00
Average Volume (3M)272.00
Market Cap
€47.94M
Enterprise Value€91.48
Total Cash (Recent Filing)€13.84M
Total Debt (Recent Filing)€24.76M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding17,640,104
10 Day Avg. Volume528
30 Day Avg. Volume272
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)14.70
Price to Sales (P/S)1.19
P/FCF Ratio-420.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)€85.00M
Bulls Say, Bears Say
Bulls Say
Improved Margins And EBITDASustained expansion to ~58% gross margin and a positive ~5% EBITDA margin indicate durable improvement in unit economics and cost structure. If top-line stabilizes, these margin gains support long-term profitability and better cash generation versus prior years.
Positive Operating Cash FlowTTM operating cash flow of ~€4.5M shows the business converts revenue into cash, reducing immediate reliance on external financing. For a capital-dependent biobank, persistent positive OCF bolsters operational continuity and provides a foundation for gradual deleveraging.
End-to-end Biobanking ModelAn integrated model—collection, lab processing, logistics and long-term storage—creates recurring revenue streams and high switching costs. Specialized infrastructure and regulatory barriers support predictable lifetime customer relationships and a defensible niche in biobanking.
Bears Say
Severe Revenue ContractionA 67% TTM revenue decline materially reduces scale economics and undermines the business's ability to cover fixed costs tied to storage and labs. Prolonged top-line weakness will reverse margin leverage gains and restrict investment capacity, harming long-term viability.
Elevated LeverageHigh leverage with debt roughly 3.3x equity leaves a thin capital buffer and increases refinancing and interest-rate vulnerability. Elevated debt limits strategic flexibility, raises solvency risk in downturns, and can force costly capital raises that dilute long-term returns.
Ongoing Net Losses And Negative ROEPersistent net losses and a ~-49% ROE show the company is destroying shareholder capital rather than creating it. Continued unprofitability can erode equity, necessitate dilutive financing, and impede reinvestment into core operations or growth initiatives over the medium term.
0NLV FAQ
What was VITA 34 AG’s price range in the past 12 months?
VITA 34 AG lowest share price was €2.66 and its highest was €9.80 in the past 12 months.
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is €47.94M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is Aug 28, 2026 which is in 10 days.
How were VITA 34 AG’s earnings last quarter?
Currently, no data Available
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Overvalued.
Does VITA 34 AG pay dividends?
VITA 34 AG does not currently pay dividends.
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
VITA 34 AG has 17,640,104 shares outstanding.
What happened to VITA 34 AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in GB:0NLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
VITA 34 AG
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.